Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 12, 1996, Pages 2809-2812

  Kelly, Brian P ^a   Furney, Synthia K ^a   Jessen, Michael T ^a   Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; FEMALE; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0029829728     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.12.2809     Document Type: Article

References (31)

1. Bloch, A. B., G. M. Cauthen, I. M. Onorato, K. G. Dansbury, G. D. Kelly, C. R. Driver, and D. E. Snider. 1994. Nationwide survey of drug-resistant tuberculosis in lhe Uniled States. JAMA 271:665-671.
2. Chapuis, L., B. Ji, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and J. H. Grosset. 1994. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am. Respir. Crit. Care Med. 150:1355-1362.
3. Collins, F. M. 1983. Kinetics of the delayed-type hypersensitivity response in tuberculous guinea pigs and mice tested with several mycobacterial antigens. Am. Rev. Respir. Dis. 127:599-604.
4. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in gamma interferon gene-disrupted mice. J. Exp. Med. 178:2243-2247.
5. Dhillon, J., J. M. Dickinson, J. A. Guy, T. K. Ng, and D. A. Mitchison. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tubercle Lung Dis. 73:116-123.
6. Dhillon, J., and D. A. Mitchison. 1992. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am. Rev. Respir. Dis. 145:212-214.
7. Dickinson, J. M., and D. A. Mitchison. 1987. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle 68:183-193.
8. Dickinson, J. M., and D. A. Mitchison. 1987. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 68:113-118.
9. Dolin, P. J., M. C. Raviglione, and A. Kochi. 1994. Global tuberculosis incidence and mortality during 1990-2000. Bull. W. H. O. 72:213-220.
10. Garay, S. M. 1996. Pulmonary tuberculosis, p. 373-441. In W. N. Rom and S. M. Garay (ed.), Tuberculosis. Little, Brown and Company, New York.
11. Gonzalez-Montaner, L. J., S. Natal, P. Yongchaiyud, and P. Olliaro. 1994. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tubercle Lung Dis. 75:341-347.
12. Heifets, L. B., P. Lindholm-Levy, and M. A. Flory. 1990. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141:626-630.
13. Hirata, T., H. Saito, H. Tomioka, K. Sato, J. Jidoi, K. Hosoe, and T. Hidaka. 1995. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:2295-2303.
14. Janes, D., C. Della Bruna, R. Rossi, and P. Olliaro. 1994. Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis. Antimicrob. Agents Chemother. 38:2346-2350.
15. Ji, B., C. Truffot-Pernot, C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J. Grosset. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am. Rev. Respir. Dis. 148:1541-1546.
16. Klemens, S. P., M. A. Grossi, and M. H. Cynamon. 1994. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 38:2245-2248.
17. Luna-Herrera, J., M. V. Reddy, and P. R. J. Gangadharam. 1995. In vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli. J. Antimicrob. Chemother. 36:355-363.
18. Luna-Herrera, J., M. V. Reddy, and P. R. J. Gangadharam. 1995. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrob. Agents Chemother. 39:440-444.
19. Neville, K., A. Bromberg, R. Bromberg, S. Bonk, B. A. Hanna, and W. N. Rom. 1994. The third epidemic - multidrug-resistant tuberculosis. Chest 105: 45-48.
20. Ordway, D. J., M. G. Sonnenberg, S. A. Donahue, J. T. Belisle, and I. M. Orme. 1995. Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect. Immun. 63:741-743.
21. Orme, I. M. 1988. A mouse model of the recrudescence of latent tuberculosis in the elderly. Am. Rev. Respir. Dis. 137:716-718.
22. Orme, I. M. 1988. Antimycobacterial activity in vivo of LM427 (rifabutin). Am. Rev. Respir. Dis. 138:1254-1257.
23. Orme, I. M., and D. N. McMurray. 1996. The immune response to tuberculosis in animals, p. 269-280. In W. N. Rom and S. Garay (ed.), Tuberculosis. Little, Brown and Company, New York.
24. Pretet, S., A. Lebeaut, R. Parrot, C. Truffot, J. Grosset, and A. T. Dinh-Xuan. 1992. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Eur. Respir. J. 5:680-684.
25. Riva, M., S. Crippa, F. Di Palma, A. M. Gerini, E. Soresi, and S. Scoccia. 1990. Disseminated tuberculosis of the central nervous system responsive to rifabutin. Ital. J. Neurol. Sci. 11:163-169.
26. Schwander, S., S. Rusch-Gerdes, A. Mateega, T. Lutalo, S. Tugume, C. Kityo, R. Rubaramira, P. Mugyenyi, A. Okwera, and R. Mugerwa. 1995. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tubercle Lung Dis. 76:210-218.
27. Sirgel, F. A., F. J. Botha, D. P. Parkin, B. W. Van De Wal, P. R. Donald, P. K. Clark, and D. A. Mitchison. 1993. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J. Antimicrob. Chemother. 32:867-875.
28. Skinner, P. S., S. K. Furney, M. R. Jacobs, G. Klopman, J. J. Ellner, and I. M. Orme. 1994. A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. Antimicrob. Agents Chemother. 38:2557-2563.
29. Stead, W. W. 1981. Tuberculosis among elderly persons: an outbreak in a nursing home. Ann. Intern. Med. 94:606-610.
30. Sudre, P., G. ten Dam, and A. Kochi. 1992. Tuberculosis: a global overview of the situation today. Bull. W. H. O. 709:149-159.
31. World Health Organization and International Union against Tuberculosis and Lung Disease. 1989. Tuberculosis and AIDS. Statement on AIDS and tuberculosis. Bull. Int. Union Tuberc. Lung Dis. 64:8-11.